2018年春季CMEF热潮、Cell颠覆癌症分类方式……|BioWeek一周事

2018-04-15 佚名 生物探索

第79届CMEF盛大召开;全球测序行业的10大巨头,中国占2席;诺华计划87亿美元现金,收购美国基因治疗公司AveXis;27篇Cell系列论文同发,颠覆癌症分类方式;个性化癌症疫苗“搞定”卵巢癌,2年生存率100%;科学家找到更好“破译”DNA秘密的方法……更多资讯,请跟随小编一起回顾吧。

1

产业动态

AI引发医学革命!联影全球创新大会震撼发布13款医疗人工智能产品

4月11日,第79届CMEF盛大召开。联影医疗携近50款全线产品强势登陆,成为最具人气的展台之一。更让人瞩目的是,同日下午,公司举办了首届联影全球创新大会uInnovation。会上,联影重磅发布uAI联影智能平台、系列新品以及未来创新走向。上千位嘉宾共同见证了这一顶级创新盛会。

GEN:全球测序行业的10大巨头,中国占2席

近日,GEN网站推出“Top 10 Sequencing Companies”榜单,盘点了全球测序行业10大巨头。其中,Illumina拔得头筹,中国企业占得2个席位,分别是华大基因(排名第三)、金唯智(排名第8)。

国家癌症中心:2018年全国最新乳腺癌报告

乳腺癌是影响女性健康的最主要的恶性肿瘤之一。根据 Globalcan2012数据,2012年全球女性乳腺癌新发病例约167.1万,标化发病率为43.1/10万,位居女性恶性肿瘤发病首位;发病率在全球范围内地区差异较为明显,发达国家和地区的乳腺癌发病率明显高于欠发达国家和地区;死亡病例约52.2万,标化死亡率为12.9/10万,位居女性恶性肿瘤死亡首位1。

2018全球最畅销药物TOP20

知名医药咨询公司Igeahub近日发布《2018年全球最畅销药物TOP20榜单》。Igeahub指出,在2017年,全球处方药市场约为8100亿美元;从2018年至2022年,该市场预计将以6%的年度复合增长率(CAGR)增长,2018年约为8110亿美元,2022年将达到10500亿美元。

诺华计划87亿美元现金,收购美国基因治疗公司AveXis

诺华公司(NOVN.EB)周一表示,其已签署协议,以87亿美元的价格收购美国基因治疗公司AveXis Inc.,作为其神经科学战略的一部分。

CMEF现场新品直击:GPS、迈瑞、联影、东软、鱼跃......

又到了一年一度的上海春季CMEF展,展会第一天现场直击,跟着乳酸菌一起看看各家新品都有哪些亮点吧!据了解,本届CMEF主题是"医疗数字化时代",众多医疗器械企业也开始涉足AI+医疗,众多AI新品让人眼前一亮。

汇聚六朝古都!中国细胞生物学学会2018年全国学术大会盛大开幕

“中国细胞生物学学会2018年全国学术大会?南京”今日在南京国际博览会议中心隆重举行,1500余名来自全国各地科研院所、高等院校等单位的代表参加了本次大会。大会为期4天,旨在促进我国细胞生物学领域研究人员的交流与合作,进一步推动中国细胞生物学学科的发展。

5个未通过!2017年教育部重点实验室评估结果正式公布

2018年4月4日,教育部科技司正式公布了2017年教育部重点实验室评估结果。经过初评、现场考察、综合评议、公示等环节,2017年信息领域56个参评实验室中,智能网络与网络安全教育部重点实验室(西安交通大学)等10个实验室评估结果为优秀;计算智能与信号处理教育部重点实验室(安徽大学)等41个实验室评估结果为良好;其余5个实验室未通过定期评估。

陈列平:免疫正常化将成为癌症免疫治疗的主要方法

4月10日-4月13日,中国细胞生物学学会2018年全国学术大会在南京盛大举行。4月10日下午,院校企业创新创业联盟委员会暨首届研讨会先行召开,来自耶鲁大学医学院、耶鲁癌症中心免疫部陈列平教授在研讨会上发表了题为“抗PD-1/PD-L1肿瘤免疫治疗:我们学到了什么“的主题演讲。

2

研究动态

里程碑!27篇Cell系列论文同发,颠覆癌症分类方式

这是癌症研究领域的一个重要里程碑!科学家们完成了对11,000多名患者肿瘤的基因测序和分析,提出了全新的肿瘤分类策略。研究人员称,是时候重新编写关于癌症的教科书了!

个性化癌症疫苗“搞定”卵巢癌,2年生存率100% | Science子刊

路德维希癌症研究所的最新一项试验性的临床试验表明,一种全新类型的个性化癌症疫苗可以在接受常规治疗的患者中,对复发的、III期和IV型卵巢癌的标准疗法进行组合,从而引发强有力的免疫反应。让人更惊喜的是,对疫苗有所响应的患者2年总生存率达到100%。

惊喜!阿尔兹海默症遗传风险有望被“纠正” | Nature子刊

ApoE4易感基因是阿尔兹海默症的一个主要遗传风险因素,它的出现甚至于会将这一神经衰退性疾病的发生概率提高12倍!但是,apoE4蛋白损伤神经细胞的机理一直是个谜。近期,科学家们找到了答案——apoE4蛋白会加剧有害蛋白的累积。更重要的是,他们研发出一种关键小分子,可以纠正apoE4蛋白造成的伤害。

《柳叶刀》子刊:效果惊人!转移性肺癌免疫联合疗法取得突破进展

在现代医学中,用单一化合物治疗肿瘤等复杂疾病显得愈加艰难。值得庆幸的是,成功的联合疗法的数量也在持续增长。近日,一项新的临床试验结果表明,一种新免疫疗法组合在控制肺癌方面效果惊人。

PNAS:科学家找到更好“破译”DNA秘密的方法

十分之一的人类基因会表达一种特殊的蛋白——转录因子(TFs),通过与基因组结合读取相应区域DNA 信息。这一结合是调控基因表达与否的关键。4月初,《PNAS》期刊最新发表一篇文章,揭示了一种新的计算工具,可以完美量化基因组中这一“蛋白-DNA”的结合。

Nature:这种脑刺激试验有助消除抑郁症

在弹吉他之前,音乐家会将琴弦调到特定的频率,以获得他们想要的音高。而从4月初开始,澳大利亚的一个神经科学家小组也开始对人脑进行类似的调节:他们希望通过实时瞄准神经元,将异常神经模式重新调节到健康状态。

驳斥Nature!首次证实:老年人可产生“新脑细胞”,且和年轻人一样多

关于成年人是否会产生新的神经元一直存在争议。上个月发表的一篇Nature论文称,我们一旦成人后,大脑海马体神经元似乎就“停产”了。然而,4月5日刊登在 Cell Stem Cell杂志上的一项新成果反驳了这一观点。

Science子刊封面:HIV感染引发免疫细胞“失效”的细节

4月6日,《Science Immunology》期刊以封面形式发表了一篇文章,揭示一种关键的免疫细胞在艾滋病患者体内失效的细节。虽然这一细胞数量z在艾滋病患者体内远多于健康人群,但是因为HIV的感染,该细胞出现功能障碍。

Nature关注:中国脑计划正式落地

大脑是宇宙中最复杂的系统之一,已成为科研界下一个必争之地。自2013年起,美国、欧洲、日本、韩国等相继启动大型脑科学项目,中国于2016年也计划推出相关项目。4月5日,《Nature》杂志发表题为“Beijing launches pioneering brain-science centre”的文章,表示备受期待的中国脑科学计划正式落地。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918038, encodeId=5a2819180388f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 28 14:40:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870572, encodeId=694418e0572d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 02 08:40:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960841, encodeId=32d91960841ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 20 20:40:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383021, encodeId=3aa91383021dd, content=<a href='/topic/show?id=651c48933b' target=_blank style='color:#2F92EE;'>#CMEF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4893, encryptionId=651c48933b, topicName=CMEF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Tue Apr 17 01:40:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306009, encodeId=7af330600993, content=好文.值得点赞!认真学习.应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Apr 15 11:21:28 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306006, encodeId=b2993060060c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Apr 15 11:17:17 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
    2019-01-28 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918038, encodeId=5a2819180388f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 28 14:40:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870572, encodeId=694418e0572d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 02 08:40:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960841, encodeId=32d91960841ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 20 20:40:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383021, encodeId=3aa91383021dd, content=<a href='/topic/show?id=651c48933b' target=_blank style='color:#2F92EE;'>#CMEF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4893, encryptionId=651c48933b, topicName=CMEF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Tue Apr 17 01:40:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306009, encodeId=7af330600993, content=好文.值得点赞!认真学习.应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Apr 15 11:21:28 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306006, encodeId=b2993060060c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Apr 15 11:17:17 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918038, encodeId=5a2819180388f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 28 14:40:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870572, encodeId=694418e0572d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 02 08:40:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960841, encodeId=32d91960841ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 20 20:40:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383021, encodeId=3aa91383021dd, content=<a href='/topic/show?id=651c48933b' target=_blank style='color:#2F92EE;'>#CMEF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4893, encryptionId=651c48933b, topicName=CMEF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Tue Apr 17 01:40:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306009, encodeId=7af330600993, content=好文.值得点赞!认真学习.应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Apr 15 11:21:28 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306006, encodeId=b2993060060c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Apr 15 11:17:17 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
    2019-02-20 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918038, encodeId=5a2819180388f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 28 14:40:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870572, encodeId=694418e0572d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 02 08:40:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960841, encodeId=32d91960841ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 20 20:40:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383021, encodeId=3aa91383021dd, content=<a href='/topic/show?id=651c48933b' target=_blank style='color:#2F92EE;'>#CMEF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4893, encryptionId=651c48933b, topicName=CMEF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Tue Apr 17 01:40:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306009, encodeId=7af330600993, content=好文.值得点赞!认真学习.应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Apr 15 11:21:28 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306006, encodeId=b2993060060c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Apr 15 11:17:17 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
    2018-04-17 anan
  5. [GetPortalCommentsPageByObjectIdResponse(id=1918038, encodeId=5a2819180388f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 28 14:40:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870572, encodeId=694418e0572d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 02 08:40:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960841, encodeId=32d91960841ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 20 20:40:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383021, encodeId=3aa91383021dd, content=<a href='/topic/show?id=651c48933b' target=_blank style='color:#2F92EE;'>#CMEF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4893, encryptionId=651c48933b, topicName=CMEF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Tue Apr 17 01:40:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306009, encodeId=7af330600993, content=好文.值得点赞!认真学习.应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Apr 15 11:21:28 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306006, encodeId=b2993060060c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Apr 15 11:17:17 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
    2018-04-15 lietome2

    好文.值得点赞!认真学习.应用于实践!谢谢分享给广大同好!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1918038, encodeId=5a2819180388f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 28 14:40:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870572, encodeId=694418e0572d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 02 08:40:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960841, encodeId=32d91960841ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 20 20:40:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383021, encodeId=3aa91383021dd, content=<a href='/topic/show?id=651c48933b' target=_blank style='color:#2F92EE;'>#CMEF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4893, encryptionId=651c48933b, topicName=CMEF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Tue Apr 17 01:40:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306009, encodeId=7af330600993, content=好文.值得点赞!认真学习.应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Apr 15 11:21:28 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306006, encodeId=b2993060060c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Apr 15 11:17:17 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
    2018-04-15 明月清辉

    谢谢分享.学习了

    0

相关资讯

Cell:超大型基因图谱研究将癌症重新“归类”

美国国家卫生研究院 资助的科学家团队完成大规模癌症基因组图谱绘制,他们根据基因变异和表达的相似性,提出可以按照分子类型给癌症“归类”。研究人员认为,这将为癌症诊断和治疗提供新思路。

Science:CAR-T细胞疗法新近进展

CAR-T细胞疗法属于过继性T细胞转移(adoptive T-cell transfer,ACT)的一种,这是输血医学的一个新领域,涉及淋巴细胞回输以实现抗肿瘤,抗病毒或抗炎作用。该领域从临床前研究到临床应用一直得到快速发展,去年我们见证了两款CAR-T细胞疗法的上市,用来治疗白血病和淋巴瘤。作为第一款上市的CAR-T细胞产品Kymriah的主要研发人员,宾夕法尼亚大学的Carl June教授等人

CA:癌症筛查阳性后必须及时跟进,否则预后变差

癌症初步筛查阳性,后续及时跟踪有多重要?近日,医学神刊《CA:A Cancer Journal for Clinicians》发布了一篇来自美国宾夕法尼亚大学科研人员的文献综述,指出如果癌症筛查阳性,如果拖延越久不去做后续的诊断性检测,那么将会大大增加发生癌症、晚期癌症和死亡的风险。这份杂志是医学领域学者奉为殿堂级的期刊,全球唯一影响因子 100 以上的杂志,2016 年度影响因子 187.04!

Br J Cancer:坚持13个健康生活方式可避免40%癌症

近期,英国癌症杂志刊登了英国癌症研究所发布的全英癌症风险归因分析报告。该报告指出,全英国,通过坚持13项健康生活方式,每年可避免近14万例癌症,这约相当于英国每年新发癌症病例的40%。

Sci Transl Med:重磅!抗癌疫苗再获突破,一名晚期患者已5年无癌

今日,《科学》杂志子刊《Science Translational Medicine》上刊登了一项令人激动的研究结果——作为全世界癌症免疫疗法的中心之一,宾夕法尼亚大学的科学家们在抗癌疫苗上做出了重大突破,有望彻底变革当下癌症治疗的格局。

Cell Metab:颠覆认知!衰老会促进癌症复发!

过去的理论认为,细胞衰老主要发挥抑制肿瘤发生作用。然而,在最近Nature的一项研究中,Milanovic等人的研究结果挑战了这种传统观点,该研究结果表明衰老可以促进癌症再发和增强肿瘤侵袭性。 这一发现表明抗衰老药物或许可以应用于抗肿瘤治疗当中。